Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9127 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.9048 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8846 |
High Similarity |
NPD1613 |
Approved |
0.8846 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8473 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.814 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.811 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8016 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7984 |
Intermediate Similarity |
NPD228 |
Approved |
0.7926 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7879 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7869 |
Intermediate Similarity |
NPD968 |
Approved |
0.7852 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7847 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7785 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7778 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7755 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7754 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.774 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7721 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7647 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7609 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7594 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.752 |
Intermediate Similarity |
NPD290 |
Approved |
0.75 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7482 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7481 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7463 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7459 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7442 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7407 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7403 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7403 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7386 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7353 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7296 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7296 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7296 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7267 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7266 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7266 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7266 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7259 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7258 |
Intermediate Similarity |
NPD940 |
Approved |
0.7258 |
Intermediate Similarity |
NPD846 |
Approved |
0.7254 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7241 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7241 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7206 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7205 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7203 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7194 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7177 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7176 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7153 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7133 |
Intermediate Similarity |
NPD943 |
Approved |
0.7117 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7115 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7113 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7091 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.708 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7078 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7078 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7075 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7055 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7055 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7049 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7047 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7047 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7029 |
Intermediate Similarity |
NPD1481 |
Phase 2 |
0.7027 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7015 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7014 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7014 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7014 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7012 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7007 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7007 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6984 |
Remote Similarity |
NPD291 |
Approved |
0.698 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.697 |
Remote Similarity |
NPD7843 |
Approved |
0.697 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.695 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.694 |
Remote Similarity |
NPD709 |
Approved |
0.694 |
Remote Similarity |
NPD7157 |
Approved |
0.6939 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6937 |
Remote Similarity |
NPD5494 |
Approved |
0.6934 |
Remote Similarity |
NPD17 |
Approved |
0.6934 |
Remote Similarity |
NPD5846 |
Approved |
0.6934 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6929 |
Remote Similarity |
NPD3225 |
Approved |
0.6923 |
Remote Similarity |
NPD7095 |
Approved |
0.6918 |
Remote Similarity |
NPD1607 |
Approved |
0.6914 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6906 |
Remote Similarity |
NPD2235 |
Phase 2 |
0.6906 |
Remote Similarity |
NPD2231 |
Phase 2 |
0.6892 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6886 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6879 |
Remote Similarity |
NPD37 |
Approved |
0.6879 |
Remote Similarity |
NPD1203 |
Approved |
0.6871 |
Remote Similarity |
NPD4538 |
Approved |
0.6871 |
Remote Similarity |
NPD4536 |
Approved |
0.6871 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD6674 |
Discontinued |
0.6867 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6863 |
Remote Similarity |
NPD7447 |
Phase 1 |
0.6861 |
Remote Similarity |
NPD3445 |
Approved |
0.6861 |
Remote Similarity |
NPD1357 |
Approved |
0.6861 |
Remote Similarity |
NPD3443 |
Approved |
0.6861 |
Remote Similarity |
NPD3444 |
Approved |
0.6859 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6855 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6855 |
Remote Similarity |
NPD844 |
Approved |
0.6855 |
Remote Similarity |
NPD4965 |
Approved |
0.6855 |
Remote Similarity |
NPD4966 |
Approved |
0.6853 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6852 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6849 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6846 |
Remote Similarity |
NPD5762 |
Approved |
0.6846 |
Remote Similarity |
NPD5763 |
Approved |
0.6842 |
Remote Similarity |
NPD7635 |
Approved |
0.6838 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD3705 |
Approved |
0.6833 |
Remote Similarity |
NPD9094 |
Approved |
0.6828 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6828 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6826 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6824 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6824 |
Remote Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.6824 |
Remote Similarity |
NPD5588 |
Approved |
0.6824 |
Remote Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.6813 |
Remote Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.6813 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6812 |
Remote Similarity |
NPD1778 |
Approved |
0.6809 |
Remote Similarity |
NPD8651 |
Approved |
0.6809 |
Remote Similarity |
NPD2922 |
Phase 1 |
0.6805 |
Remote Similarity |
NPD8053 |
Approved |
0.6805 |
Remote Similarity |
NPD8054 |
Approved |
0.68 |
Remote Similarity |
NPD288 |
Approved |
0.6797 |
Remote Similarity |
NPD7213 |
Phase 3 |
0.6797 |
Remote Similarity |
NPD1774 |
Approved |
0.6797 |
Remote Similarity |
NPD7212 |
Phase 2 |
0.6797 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6795 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6792 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6792 |
Remote Similarity |
NPD2560 |
Approved |
0.6792 |
Remote Similarity |
NPD2563 |
Approved |
0.679 |
Remote Similarity |
NPD1247 |
Approved |
0.6788 |
Remote Similarity |
NPD1182 |
Approved |
0.6788 |
Remote Similarity |
NPD7228 |
Approved |
0.6786 |
Remote Similarity |
NPD2233 |
Approved |
0.6786 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6786 |
Remote Similarity |
NPD2232 |
Approved |
0.6786 |
Remote Similarity |
NPD2230 |
Approved |
0.6783 |
Remote Similarity |
NPD9494 |
Approved |
0.6781 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6779 |
Remote Similarity |
NPD6032 |
Approved |
0.6776 |
Remote Similarity |
NPD2677 |
Approved |
0.6759 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6759 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6759 |
Remote Similarity |
NPD3268 |
Approved |
0.6755 |
Remote Similarity |
NPD3060 |
Approved |
0.6753 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6738 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6738 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6736 |
Remote Similarity |
NPD596 |
Approved |
0.6736 |
Remote Similarity |
NPD600 |
Approved |
0.6735 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6733 |
Remote Similarity |
NPD7266 |
Discontinued |
0.6733 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6732 |
Remote Similarity |
NPD7124 |
Phase 2 |
0.6727 |
Remote Similarity |
NPD7473 |
Discontinued |
0.672 |
Remote Similarity |
NPD2859 |
Approved |
0.672 |
Remote Similarity |
NPD2860 |
Approved |
0.6716 |
Remote Similarity |
NPD5535 |
Approved |
0.6711 |
Remote Similarity |
NPD3748 |
Approved |
0.6711 |
Remote Similarity |
NPD651 |
Clinical (unspecified phase) |
0.6711 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.671 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6708 |
Remote Similarity |
NPD4055 |
Discovery |
0.6708 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6693 |
Remote Similarity |
NPD3020 |
Approved |
0.6692
|
Remote Similarity |
NPD9697 |
Approved |